Quiz Form
Quiz Form
Quiz Listing
Edit Question
1
2
3
Question Date
*
Please select a valid date.
Question
*
Which of the following is not true regarding aducanumab?
Explanation
*
Aducanumab is the first monoclonal antibody FDA approved in June 2021 for the treatment of MCI due to AD and mild AD Dementia (MMSE> 23, Clinical Dementia Rating CDR of 0.5)<br><br>It is an anti Amyloid Beta immunotherapy that has demonstrated significant reduction in amyloid beta plaque burden as demonstrated by amyloid PET scan<br><br>The highest risk factor for ARIA is the presence of APOE4 allele.(40%, compared to 20% for non APOE4 allele patients)<br><br>40% patients on treatment with aducanumab had ARIA (Amyloid related imaging abnormalities) on MRI, and 7 % discontinued.
Explanation Image Upload:
(JPG / JPEG / PNG Upto 2 MB only)
Reference
*
CONTINUUM (MINNEAP MINN) 2022;28(3, DEMENTIA):648-675<br><br>CONTINUUM (MINNEAP MINN) 2022;28(3,DEMENTIA):800-821<br><br>Alzheimers Dement. 2011 July ; 7(4): 367?385
Reference Image Upload:
(JPG / JPEG / PNG Upto 2 MB only)
Question Image Upload:
(JPG / JPEG / PNG Upto 2 MB only)
Video Upload:
(MP4 / Upto 10 MB only)
Option 1
*
Is Correct (Option 1):
It is the first monoclonal antibody FDA approved in June 2021 for the treatment of mild to moderate Alzheimer's disease.
Option 1 Image Upload:
(JPG / JPEG / PNG Upto 2 MB only)
Option 2
*
Is Correct (Option 2):
It is an anti Amyloid Beta immunotherapy that has demonstrated significant reduction in amyloid beta plaque burden as demonstrated by amyloid PET scan.
Option 2 Image Upload:
(JPG / JPEG / PNG Upto 2 MB only)
Option 3
*
Is Correct (Option 3):
40 % patients on treatment with aducanumab had ARIA (Amyloid related imaging abnormalities) on MRI
Option 3 Image Upload:
(JPG / JPEG / PNG Upto 2 MB only)
Option 4
*
Is Correct (Option 4):
The highest risk factor for ARIA is the presence of APOE4 allele
Option 4 Image Upload:
(JPG / JPEG / PNG Upto 2 MB only)
